cyy-287, a novel pyrimidine-2,4-diamine derivative, inhibits tumor growth of EGFR-driven non-small cell lung cancer via the ERK pathway
Sign Up to like & getrecommendations! Published in 2022 at "Acta Biochimica et Biophysica Sinica"
DOI: 10.3724/abbs.2022139
Abstract: In recent decades, EGFR-targeted tyrosine kinase inhibitors (TKIs) have been proven to be an effective therapy for EGFR-mutant non-small cell lung cancer (NSCLC). However, resistance to EGFR-TKIs limits their clinical application. In the present study,… read more here.
Keywords: erk pathway; cyy 287; non small; egfr driven ... See more keywords